MedPath

Trial Comparing Loop Ileostomy Versus Loop Transverse Colostomy

Not Applicable
Active, not recruiting
Conditions
Rectal Neoplasms
Ostomy
Neoplasms
Interventions
Procedure: Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy
Procedure: Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy
Registration Number
NCT05745909
Lead Sponsor
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
Brief Summary

The purpose of this study is to determine which stoma creation technique is preferable after low anterior resection of the rectum.

Detailed Description

The investigators enroll patients with a histologically confirmed diagnosis of primary rectal cancer with or without prior chemoradiotherapy who were hospitalized at the Ufa Republican Clinical Oncology Center from February 2023 to February 2024.

All patients undergo planned laparoscopic or open low-anterior resection of the rectum with total mesorectal excision. Patients are randomized into 2 groups in a 1:1 ratio. In the first group, a loop transverse colostomy is created, and in the second group, a loop ileostomy is created. The stoma exit sites are marked in advance the day before the surgery. The bowels are prepared by mechanical means (a polyethylene glycol-based laxative with a cleansing enema) according to a standard procedure before the surgery. Standardized stoma creation techniques are used. The resected parts are collected through a separate access. Patients are followed up for 60 days after surgery.

The sample size should be 124 patients to reach statistical significance (α = 0.05, study power 80%, confidence interval (CI) = 95%.). Considering possible losses during the study, the number of patients was increased to 130.

The investigators hypothesis is that the loop ileostomy group has a 20% higher incidence of stoma dysfunction but a 20% lower incidence of SSI (stoma site infections) compared to the loop colostomy group.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Histologically confirmed adenocarcinoma of the rectum (stages 1-3 according to MRI)
  • ECOG status 0-2,
  • ASA≤3.
  • At least 18 years of age
  • Written informed consent
Exclusion Criteria
  • Emergency surgery;
  • Previously formed stoma;
  • Stage 4 disease;
  • Obstructive resection of the rectum;
  • Patients older than 79 years

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Loop ileostomyLaparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomyLaparoscopic or open low-anterior resection of the rectum with total mesorectal excision and created loop ileostomy
Loop transverse colostomyLaparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomyLaparoscopic or open low-anterior resection of the rectum with total mesorectal excision and created loop transverse colostomy
Primary Outcome Measures
NameTimeMethod
SSI60 days after surgery

incidence of stoma site infections

Ileus60 days after surgery

incidence of stoma dysfunction

Secondary Outcome Measures
NameTimeMethod
Time to adjuvant postoperative chemotherapywithin the first 2 months days after surgery

the number of days from surgery to hospitalization for first chemotherapy

Readmission ratewithin the first 60 days after surgery

readmission rate

Length of hospital stayFrom date of surgery until the date of discharge, assessed up to 60 days

the number of days from surgery to discharge

Quality of life in patients with ostomywithin the first 60 days after surgery

estimated using EORTC QLQ-CR29

Time to first stool60 days after surgery

the occurrence of anything other than serous-hemorrhagic contents in the colostomy bag

Time to stoma closurewithin the first 6 months days after surgery

the number of days from surgery to stoma closure

Trial Locations

Locations (1)

Republican clinical oncological dispencery

🇷🇺

Ufa, Republic Of Bashkortostan, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath